XF-73 is ‘The Real Deal’
With Destiny’s lead drug now licensed to Sebela Pharmaceuticals in preparation for its Phase 3...
Read moreGrowth rate head-and-shoulders above peers (again)
AUM grew 8% over H1-24 (to 30 Sep 23) from £12.7bn to £13.7bn. Net inflows totalled £910m (7% of...
Read morePositive trading update and vaping safety measures
In a Trading Update for the six months to 30 September 2023, Supreme reports strong performance in...
Read morePositive year-end update, ahead of expectations
A positive year-end update from Hercules confirms a strong conclusion to FY23, ahead of...
Read moreLand sale – delivering on cash generation strategy
Springfield has announced the sale of c.9.5 acres of land for £5.2m in cash (£0.5m to be received...
Read moreService uplift sparks 25% sales growth
Marks Electrical Group’s sales revenue advanced by 24.8% in the first half of its 2024 financial...
Read moreSolid H1 amidst sharp sector share-price falls
AUM was slightly down (-0.4%) to £19.14bn over H1-24 (to 30 Sep 23), with a -2.9% fall in Q2...
Read moreWell-flagged sluggish quarter but price fall looks over-done
FUM increased marginally over Q1 of FY24 from £16.85bn on 30 Jun 23 to £16.86bn on 30 Sep 23. As...
Read moreParsing the Akamai deal ... and a conversation with Corero's Chief Technology Officer
Corero Network Security signed a global partnership with Akamai in September. This agreement is...
Read moreResilient H1 performance, compelling valuation
Vp traded resiliently through H1’24 against a backdrop of challenging macro-economic conditions,...
Read moreRecent newsflow points to strength in diversity
Hercules has recently released two positive contract announcements, highlighting continuing...
Read moreSector-leading growth, but 3rd quartile valuation
AUM closed FY23 (30 Sep 23) on £37.4bn, 5% up y-o-y. Net flows were slightly negative at -£92m,...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
